Role of transcription factors in cell replacement therapies for neurodegenerative conditions

Regenerative Medicine

Volumn 5, Issue 3, 2010, Pages 441-450

  Thomas, Meghan ^a,b  

^a EDITH COWAN UNIVERSITY   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Cell therapy; Development; Dopaminergic; Neurogenesis; Neurons; Parkinson's disease; Stem cell; Transcription factor

Indexed keywords

OCTAMER TRANSCRIPTION FACTOR 4; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; VIRUS VECTOR; DOPAMINE;

CELL BASED GENE THERAPY; CELL DIFFERENTIATION; CELL THERAPY; DOPAMINERGIC NERVE CELL; EMBRYONIC STEM CELL; FETAL TISSUE TRANSPLANTATION; HUMAN; INNER CELL MASS; MESENCEPHALON; NERVE DEGENERATION; NERVOUS SYSTEM DEVELOPMENT; NEURAL TUBE; NEUROANATOMY; NONHUMAN; PARKINSON DISEASE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; RHOMBENCEPHALON; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA; VIRAL GENE DELIVERY SYSTEM; ANIMAL; BIOLOGICAL THERAPY; BLASTOCYST; METABOLISM; MITOSIS; MOUSE; NERVE CELL; NEURODEGENERATIVE DISEASES; PROCEDURES; REGENERATIVE MEDICINE; STEM CELL TRANSPLANTATION;

ANIMALS; BLASTOCYST; CELL DIFFERENTIATION; CELL- AND TISSUE-BASED THERAPY; DOPAMINE; HUMANS; MICE; MITOSIS; NEURODEGENERATIVE DISEASES; NEURONS; PARKINSON DISEASE; REGENERATIVE MEDICINE; STEM CELL TRANSPLANTATION; SUBSTANTIA NIGRA; TRANSCRIPTION FACTORS;

EID: 77952244110     PISSN: 17460751     EISSN: None     Source Type: Journal    
DOI: 10.2217/rme.10.17     Document Type: Review

References (83)

1. Hosing C, Saliba RM, Mclaughlin P et al.: Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-hodgkin's lymphoma. Ann. Oncol. 14(5), 737-744 (2003).
2. Couri CE, Oliveira MC, Stracieri AB et al.: C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed Type 1 diabetes mellitus. JAMA 301(15), 1573-1579 (2009).
3. Voltarelli JC, Couri CE, Stracieri AB et al.: Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed Type 1 diabetes mellitus. JAMA 297(14), 1568-1576 (2007).
4. Buchholz DE, Hikita ST, Rowland TJ et al.: Derivation of functional retinal pigmented epithelium from induced pluripotent stem cells. Stem Cells 27(10), 2427-2434 (2009).
5. Tezel TH, Del Priore LV, Berger AS, Kaplan HJ: Adult retinal pigment epithelial transplantation in exudative age-related macular degeneration. Am. J. Ophthalmol. 143(4), 584-595 (2007).
6. Ericson J, Morton S, Kawakami A, Roelink H, Jessell TM: Two critical periods of sonic hedgehog signaling required for the specification of motor neuron identity. Cell 87(4), 661-673 (1996).
7. Wurst W, Bally-Cuif L: Neural plate patterning: upstream and downstream of the isthmic organizer. Nat. Rev. Neurosci. 2(2), 99-108 (2001).
8. Staudt N, Houart C: The prethalamus is established during gastrulation and influences diencephalic regionalization. PLoS Biol. 5(4), e69 (2007).
9. Puelles L, Martinez-De-La-Torre M, Paxinos G, Watson C, Martinez S: The Chick Brain in Stereotaxic Coordinates (1st Edition). Academic Press, CA, USA (2007).
10. Muller CW: Transcription factors: global and detailed views. Curr. Opin. Struct. Biol. 11(1), 26-32 (2001).
11. Ouzounis CA, Papavassiliou AG: DNA-Binding Motifs of Eukaryotic Transcription Factors. Landes Bioscience, Austin, TX, USA 1-13 (1997).
12. Barker RA, Dunnett SB: Functional integration of neural grafts in Parkinson's disease. Nat. Neurosci. 2(12), 1047-1048 (1999).
13. Freed CR, Breeze RE, Rosenberg NL et al.: Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease. N. Engl. J. Med. 327(22), 1549-1555 (1992).
14. Piccini P, Brooks DJ, Bjorklund A et al.: Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. Nat. Neurosci. 2(12), 1137-1140 (1999).
15. Kuan WL, Lin R, Tyers P, Barker RA: The importance of A9 dopaminergic neurons in mediating the functional benefits of fetal ventral mesencephalon transplants and levodopa-induced dyskinesias. Neurobiol. Dis. 25(3), 594-608 (2007).
16. Thompson L, Barraud P, Andersson E, Kirik D, Bjorklund A: Identification of dopaminergic neurons of nigral and ventral tegmental area subtypes in grafts of fetal ventral mesencephalon based on cell morphology, protein expression, and efferent projections. J. Neurosci. 25(27), 6467-6477 (2005).
17. Wijeyekoon R, Barker RA: Cell replacement therapy for Parkinson's disease. Biochim. Biophys. Acta 1792(7), 688-702 (2009).
18. Park CH, Minn YK, Lee JY et al.: In vitro and in vivo analyses of human embryonic stem cell-derived dopamine neurons. J. Neurochem. 92(5), 1265-1276 (2005).
19. Perrier AL, Tabar V, Barberi T et al.: Derivation of midbrain dopamine neurons from human embryonic stem cells. Proc. Natl Acad. Sci. USA 101(34), 12543-12548 (2004).
20. Zeng X, Cai J, Chen J et al.: Dopaminergic differentiation of human embryonic stem cells. Stem Cells 22(6), 925-940 (2004). (Pubitemid 39507080)
21. Chen Q, Long Y, Yuan X et al.: Protective effects of bone marrow stromal cell transplantation in injured rodent brain: Synthesis of neurotrophic factors. J. Neurosci. Res. 80(5), 611-619 (2005).
22. Crigler L, Robey RC, Asawachaicharn A, Gaupp D, Phinney DG: Human mesenchymal stem cell subpopulations express a variety of neuro-regulatory molecules and promote neuronal cell survival and neuritogenesis. Exp. Neurol. 198(1), 54-64 (2006).
23. Vazin T, Chen J, Lee CT, Amable R, Freed WJ: Assessment of stromal-derived inducing activity in the generation of dopaminergic neurons from human embryonic stem cells. Stem Cells 26(6), 1517-1525 (2008).
24. Vazin T, Becker KG, Chen J et al.: A novel combination of factors, termed spie, which promotes dopaminergic neuron differentiation from human embryonic stem cells. PLoS One 4(8), e6606 (2009).
25. Davis RL, Weintraub H, Lassar AB: Expression of a single transfected cDNA converts fibroblasts to myoblasts. Cell 51(6), 987-1000 (1987).
26. Takahashi K, Yamanaka S: Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126(4), 663-676 (2006).
27. Takahashi K, Tanabe K, Ohnuki M et al.: Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131(5), 861-872 (2007).
28. Yu J, Vodyanik MA, Smuga-Otto K et al.: Induced pluripotent stem cell lines derived from human somatic cells. Science 318(5858), 1917-1920 (2007).
29. Nagy A, Nagy K: The mysteries of induced pluripotency: where will they lead? Nat. Methods 7(1), 22-24 (2010).
30. Marchand R, Poirier LJ: Isthmic origin of neurons of the rat substantia nigra. Neuroscience 9(2), 373-381 (1983).
31. Wallen A, Perlmann T: Transcriptional control of dopamine neuron development. Ann. NY Acad. Sci. 991, 48-60 (2003).
32. Puelles L, Rubenstein JL: Forebrain gene expression domains and the evolving prosomeric model. Trends Neurosci. 26(9), 469-476 (2003).
33. Boyer LA, Lee TI, Cole MF et al.: Core transcriptional regulatory circuitry in human embryonic stem cells. Cell 122(6), 947-956 (2005).
34. Chew JL, Loh YH, Zhang W et al.: Reciprocal transcriptional regulation of Pou5f1 and Sox2 via the Oct4/Sox2 complex in embryonic stem cells. Mol. Cell. Biol. 25(14), 6031-6046 (2005).
35. Mitsui K, Tokuzawa Y, Itoh H et al.: The homeoprotein nanog is required for maintenance of pluripotency in mouse epiblast and ES cells. Cell 113(5), 631-642 (2003).
36. Nishikawa S-I, Jakt LM, Era T: Embryonic stem-cell culture as a tool for developmental cell biology. Nat. Rev. Mol. Cell. Biol. 8(6), 502-507 (2007).
37. Woltjen K, Michael IP, Mohseni P et al.: Piggybac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature 458(7239), 766-770 (2009).
38. Nichols J, Zevnik B, Anastassiadis K et al.: Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription factor Oct4. Cell 95(3), 379-391 (1998).
39. Sommer CA, Stadtfeld M, Murphy GJ, Hochedlinger K, Kotton DN, Mostoslavsky G: Induced pluripotent stem cell generation using a single lentiviral stem cell cassette. Stem Cells 27(3), 543-549 (2009).
40. Wernig M, Meissner A, Foreman R et al.: In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature 448(7151), 318-324 (2007). (Pubitemid 47080337)
41. Wernig M, Meissner A, Cassady JP, Jaenisch R: C-Myc is dispensable for direct reprogramming of mouse fibroblasts. Cell Stem Cell 2(1), 10-12 (2008).
42. Bertrand N, Castro DS, Guillemot F: Proneural genes and the specification of neural cell types. Nat. Rev. Neurosci. 3(7), 517-530 (2002).
43. Ostenfeld T, Joly E, Tai YT et al.: Regional specification of rodent and human neurospheres. Brain Res. Dev. Brain Res. 134(1-2), 43-55 (2002).
44. Parmar M, Skogh C, Bjorklund A, Campbell K: Regional specification of neurosphere cultures derived from subregions of the embryonic telencephalon. Mol. Cell Neurosci. 21(4), 645-656 (2002).
45. Hitoshi S, Tropepe V, Ekker M, Van Der Kooy D: Neural stem cell lineages are regionally specified, but not committed, within distinct compartments of the developing brain. Development 129(1), 233-244 (2002).
46. Ericson J, Rashbass P, Schedl A et al.: Pax6 controls progenitor cell identity and neuronal fate in response to graded Shh signaling. Cell 90(1), 169-180 (1997).
47. Stoykova A, Gruss P: Roles of Pax-genes in developing and adult brain as suggested by expression patterns. J. Neurosci. 14(3 Pt 2), 1395-1412 (1994).
48. Tanabe Y, Jessell TM: Diversity and pattern in the developing spinal cord. Science 274(5290), 1115-1123 (1996).
49. Lee SK, Pfaff SL: Transcriptional networks regulating neuronal identity in the developing spinal cord. Nat. Neurosci. 4(Suppl.), 1183-1191 (2001).
50. Kittappa R, Chang WW, Awatramani RB, Mckay RD: The foxa2 gene controls the birth and spontaneous degeneration of dopamine neurons in old age. PLoS Biol. 5(12), e325 (2007).
51. Rhinn M, Dierich A, Le Meur M, Ang S: Cell autonomous and non-cell autonomous functions of Otx2 in patterning the rostral brain. Development 126(19), 4295-4304 (1999).
52. Araki I, Nakamura H: Engrailed defines the position of dorsal di-mesencephalic boundary by repressing diencephalic fate. Development 126(22), 5127-5135 (1999).
53. Matsunaga E, Araki I, Nakamura H: Pax6 defines the di-mesencephalic boundary by repressing En1 and Pax2. Development 127(11), 2357-2365 (2000).
54. Crossley PH, Martinez S, Martin GR: Midbrain development induced by FGF8 in the chick embryo. Nature 380(6569), 66-68 (1996).
55. Shamim H, Mahmood R, Logan C, Doherty P, Lumsden A, Mason I: Sequential roles for FGF4, En1 and FGF8 in specification and regionalisation of the midbrain. Development 126(5), 945-959 (1999).
56. Simeone A, Acampora D, Gulisano M, Stornaiuolo A, Boncinelli E: Nested expression domains of four homeobox genes in developing rostral brain. Nature 358(6388), 687-690 (1992).
57. Wassarman KM, Lewandoski M, Campbell K et al.: Specification of the anterior hindbrain and establishment of a normal mid/hindbrain organizer is dependent on gbx2 gene function. Development 124(15), 2923-2934 (1997).
58. Broccoli V, Boncinelli E, Wurst W: The caudal limit of otx2 expression positions the isthmic organizer. Nature 401(6749), 164-168 (1999).
59. Scholpp S, Lohs C, Brand M: Engrailed and FGF8 act synergistically to maintain the boundary between diencephalon and mesencephalon. Development 130(20), 4881-4893 (2003).
60. Okafuji T, Funahashi J, Nakamura H: Roles of Pax-2 in initiation of the chick tectal development. Brain Res. Dev. Brain Res. 116(1), 41-49 (1999).
61. Funahashi J, Okafuji T, Ohuchi H, Noji S, Tanaka H, Nakamura H: Role of Pax-5 in the regulation of a mid-hindbrain organizer's activity. Dev. Growth Differ. 41(1), 59-72 (1999).
62. Lee SM, Danielian PS, Fritzsch B, McMahon AP: Evidence that FGF8 signalling from the midbrain-hindbrain junction regulates growth and polarity in the developing midbrain. Development 124(5), 959-969 (1997).
63. Nakamura H: Regionalization of the optic tectum: combinations of gene expression that define the tectum. Trends Neurosci. 24(1), 32-39 (2001).
64. Mastick GS, Davis NM, Andrew GL, Easter SS Jr: Pax-6 functions in boundary formation and axon guidance in the embryonic mouse forebrain. Development 124(10), 1985-1997 (1997).
65. Thompson JA, Lovicu FJ, Ziman M: Pax7 and superior collicular polarity: insights from Pax6 (Sey) mutant mice. Exp. Brain Res. 178(3), 316-325 (2007).
66. Matsunaga E, Araki I, Nakamura H: Role of Pax3/7 in the tectum regionalization. Development 128(20), 4069-4077 (2001).
67. Abeliovich A, Hammond R: Midbrain dopamine neuron differentiation: factors and fates. Dev. Biol. 304(2), 447-454 (2007).
68. Perlmann T, Wallen-Mackenzie A: Nurr1, an orphan nuclear receptor with essential functions in developing dopamine cells. Cell Tissue Res. 318(1), 45-52 (2004).
69. Levesque D, Rouillard C: Nur77 and retinoid X receptors: crucial factors in dopamine-related neuroadaptation. Trends Neurosci. 30(1), 22-30 (2007).
70. Prakash N, Wurst W: Development of dopaminergic neurons in the mammalian brain. Cell. Mol. Life Sci. 63(2), 187-206 (2006).
71. Chung S, Sonntag KC, Andersson T et al.: Genetic engineering of mouse embryonic stem cells by Nurr1 enhances differentiation and maturation into dopaminergic neurons. Eur. J. Neurosci. 16(10), 1829-1838 (2002).
72. Kim JH, Auerbach JM, Rodriguez-Gomez JA et al.: Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease. Nature 418(6893), 50-56 (2002).
73. Sonntag KC, Simantov R, Kim KS, Isacson O: Temporally induced Nurr1 can induce a non-neuronal dopaminergic cell type in embryonic stem cell differentiation. Eur. J. Neurosci. 19(5), 1141-1152 (2004).
74. Smidt MP, Burbach JPH: How to make a mesodiencephalic dopaminergic neuron. Nat. Rev. Neurosci. 8(1), 21-32 (2007).
75. Smidt MP, Smits SM, Burbach JP: Molecular mechanisms underlying midbrain dopamine neuron development and function. Eur. J. Pharmacol. 480(1-3), 75-88 (2003).
76. Smidt MP, Smits SM, Bouwmeester H et al.: Early developmental failure of substantia nigra dopamine neurons in mice lacking the homeodomain gene Pitx3. Development 131, 1145-1155 (2004).
77. Fluri DA, Baba MD, Fussenegger M: Adeno-associated viral vectors engineered for macrolide-adjustable transgene expression in mammalian cells and mice. BMC Biotechnol. 7, 75 (2007).
78. Varas F, Stadtfeld M, De Andres-Aguayo L et al.: Fibroblast-derived induced pluripotent stem cells show no common retroviral vector insertions. Stem Cells 27(2), 300-306 (2009).
79. Zhou W, Freed CR: Adenoviral gene delivery can reprogram human fibroblasts to induced pluripotent stem cells. Stem Cells 27(11), 2667-2674 (2009).
80. Collinson JM, Chanas SA, Hill RE, West JD: Corneal development, limbal stem cell function, and corneal epithelial cell migration in the Pax6+/- mouse. Invest. Ophthalmol. Vis. Sci. 45(4), 1101-1108 (2004).
81. Lesaffre B, Joliot A, Prochiantz A, Volovitch M: Direct non-cell autonomous Pax6 activity regulates eye development in the zebrafish. Neural Develop. 2, 2 (2007).
82. Prochiantz A, Joliot A: Can transcription factors function as cell-cell signalling molecules? Nat. Rev. Mol. Cell. Biol. 4(10), 814-819 (2003).
83. Thomas M, Tyers P, Lazic SE, Barker RA, Beazley L, Ziman M: Graft outcomes influenced by co-expression of Pax7 in graft and host tissue. J. Anat. 214(3), 396-405 (2009).